欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
VCH-916_1200133-34-1_产品详情
1200133-34-1
  • names:

    VCH-916

  • CAS号:

    1200133-34-1

    MDL Number:
  • MF(分子式): C26H36KNO4S MW(分子量): 497.73
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
VCH-916
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM000585-5mg 5mg 99.51% ¥ 2632.50 ¥ 2632.50 2-3天
- +
¥ 0.00
YZM000585-2mg 2mg 99.51% ¥ 1560.00 ¥ 1560.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 1200133-34-1
Inchi
InchiKey
分子式 Formula C26H36KNO4S
分子量 Molecular Weight 497.73
溶解度Solubility 生物体外In Vitro:DMSO溶解度≥ 39 mg/mL(78.36 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
VCH-916(CAS:1200133-34-1)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value:
IntroductionVCH16 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value:
Application1
Application2
Application3
VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value: Target: HCV VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92
【2】.Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161.
【3】.Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703
【4】.Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164
【5】.Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents